Cyclin D1 expression in mutant non-small cell lung cancer-old wine into new skins.
作者信息
Goh Kah Yee, Lim Wan-Teck
机构信息
Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
Office of Academic and Clinical Development, Duke-NUS Medical School, Singapore.
出版信息
Transl Lung Cancer Res. 2020 Dec;9(6):2302-2304. doi: 10.21037/tlcr-20-639.
Abstract
摘要
相似文献
1
Cyclin D1 expression in mutant non-small cell lung cancer-old wine into new skins.细胞周期蛋白D1在突变型非小细胞肺癌中的表达——旧瓶装新酒。
Transl Lung Cancer Res. 2020 Dec;9(6):2302-2304. doi: 10.21037/tlcr-20-639.
2
Cyclin D1 expression as a potential prognostic factor in advanced -mutant non-small cell lung cancer.细胞周期蛋白D1表达作为晚期突变型非小细胞肺癌的潜在预后因素
Transl Lung Cancer Res. 2019 Dec;8(6):959-966. doi: 10.21037/tlcr.2019.12.01.
3
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.贝沙罗汀联合厄洛替尼在两项临床试验和转基因模型中独立于 KRAS 突变抑制肺癌发生。
Cancer Prev Res (Phila). 2011 Jun;4(6):818-28. doi: 10.1158/1940-6207.CAPR-10-0376.
4
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.PIK3CA 突变使肿瘤生长和细胞周期蛋白 D1 的调节与 MEK/ERK 和突变 KRAS 信号脱耦。
Cancer Res. 2010 Sep 1;70(17):6804-14. doi: 10.1158/0008-5472.CAN-10-0409. Epub 2010 Aug 10.
5
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.RAF 抑制剂 LY3009120 通过更好地抑制磷酸化 RB 和抑制细胞周期蛋白 D1，使 RAS 或 BRAF 突变型癌症对 abemaciclib 的 CDK4/6 抑制敏感。
Oncogene. 2018 Feb 8;37(6):821-832. doi: 10.1038/onc.2017.384. Epub 2017 Oct 23.
6
Expression and role of EGFR, cyclin D1 and KRAS in laryngocarcinoma tissues.表皮生长因子受体（EGFR）、细胞周期蛋白D1（cyclin D1）及KRAS在喉癌组织中的表达及作用
Exp Ther Med. 2019 Jan;17(1):782-790. doi: 10.3892/etm.2018.7027. Epub 2018 Nov 28.
7
A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.CDK4/6 抑制剂增强了携带突变型 KRAS 和野生型 KRAS 的肺腺癌细胞中紫杉醇的细胞毒性。
Cancer Biol Ther. 2013 Jul;14(7):597-605. doi: 10.4161/cbt.24592. Epub 2013 May 10.
8
Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome.CCND1过表达与非小细胞肺癌特定亚型中KRAS和PTEN改变的关联及其对患者预后的影响。
Tumour Biol. 2015 Nov;36(11):8773-80. doi: 10.1007/s13277-015-3620-y. Epub 2015 Jun 9.
9
Galectin-3 and cyclin D1 expression in non-small cell lung cancer.半乳糖凝集素-3 和细胞周期蛋白 D1 在非小细胞肺癌中的表达。
J Exp Clin Cancer Res. 2011 Oct 24;30(1):101. doi: 10.1186/1756-9966-30-101.
10
Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.靶向 CDK4/ Cyclin D 界面的订书肽与 Abemaciclib 联合抑制 KRAS 突变型肺癌生长。
Theranostics. 2020 Jan 12;10(5):2008-2028. doi: 10.7150/thno.40971. eCollection 2020.
引用本文的文献
1
The Role of AKR1B10 in Lung Cancer Malignancy Induced by Sublethal Doses of Chemotherapeutic Drugs.AKR1B10在亚致死剂量化疗药物诱导的肺癌恶性肿瘤中的作用
Cancers (Basel). 2024 Jul 1;16(13):2428. doi: 10.3390/cancers16132428.
2
Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.在一家公立医疗医院中，使用下一代测序进行分子检测对非小细胞肺癌患者临床管理的影响。
Cancers (Basel). 2023 Mar 10;15(6):1705. doi: 10.3390/cancers15061705.
3
Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors.肽和小分子抑制剂对K-Ras结构域及突变的多靶点作用
PLoS Comput Biol. 2022 Apr 26;18(4):e1009962. doi: 10.1371/journal.pcbi.1009962. eCollection 2022 Apr.
本文引用的文献
1
Cyclin D1 expression as a potential prognostic factor in advanced -mutant non-small cell lung cancer.细胞周期蛋白D1表达作为晚期突变型非小细胞肺癌的潜在预后因素
Transl Lung Cancer Res. 2019 Dec;8(6):959-966. doi: 10.21037/tlcr.2019.12.01.
2
Cracking KRAS.破解KRAS基因
Nat Rev Drug Discov. 2019 Nov;18(12):887-891. doi: 10.1038/d41573-019-00195-5.
3
The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.KRAS 抑制剂 MRTX849 为 KRAS 突变型癌症在小鼠模型和患者中的治疗敏感性提供了新的见解。
Cancer Discov. 2020 Jan;10(1):54-71. doi: 10.1158/2159-8290.CD-19-1167. Epub 2019 Oct 28.
4
New Horizons in -Mutant Lung Cancer: Dawn After Darkness.- 突变型肺癌的新视野：黑暗后的曙光
Front Oncol. 2019 Sep 25;9:953. doi: 10.3389/fonc.2019.00953. eCollection 2019.
5
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
6
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.KRAS 致癌基因在非小细胞肺癌中的临床治疗：一个老靶点的新视角。
Mol Cancer. 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x.
7
Non-small cell lung cancer: current treatment and future advances.非小细胞肺癌：当前治疗与未来进展。
Transl Lung Cancer Res. 2016 Jun;5(3):288-300. doi: 10.21037/tlcr.2016.06.07.
8
Lung Cancer Statistics.肺癌统计数据。
Adv Exp Med Biol. 2016;893:1-19. doi: 10.1007/978-3-319-24223-1_1.
9
Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome.CCND1过表达与非小细胞肺癌特定亚型中KRAS和PTEN改变的关联及其对患者预后的影响。
Tumour Biol. 2015 Nov;36(11):8773-80. doi: 10.1007/s13277-015-3620-y. Epub 2015 Jun 9.
10
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).非小细胞肺癌中的突变发生率和一致性：基于种族和组织学的荟萃分析（mutMap）。
Ann Oncol. 2013 Sep;24(9):2371-6. doi: 10.1093/annonc/mdt205. Epub 2013 May 30.
Zotero 插件